Agios Pharmaceuticals (AGIO) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$561.7 million.
- Agios Pharmaceuticals' Retained Earnings fell 27717.56% to -$561.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$561.7 million, marking a year-over-year decrease of 27717.56%. This contributed to the annual value of -$561.7 million for FY2025, which is 27717.56% down from last year.
- Per Agios Pharmaceuticals' latest filing, its Retained Earnings stood at -$561.7 million for Q4 2025, which was down 27717.56% from -$453.7 million recorded in Q3 2025.
- Agios Pharmaceuticals' 5-year Retained Earnings high stood at $30.8 million for Q1 2021, and its period low was -$1.0 billion during Q2 2024.
- Moreover, its 5-year median value for Retained Earnings was -$439.5 million (2022), whereas its average is -$429.5 million.
- Its Retained Earnings has fluctuated over the past 5 years, first surged by 10198.22% in 2021, then tumbled by 118114.75% in 2022.
- Agios Pharmaceuticals' Retained Earnings (Quarter) stood at -$238.8 million in 2021, then crashed by 97.09% to -$470.6 million in 2022, then tumbled by 74.82% to -$822.6 million in 2023, then surged by 81.9% to -$148.9 million in 2024, then crashed by 277.18% to -$561.7 million in 2025.
- Its Retained Earnings was -$561.7 million in Q4 2025, compared to -$453.7 million in Q3 2025 and -$350.2 million in Q2 2025.